Improving Lives Through Nuclear Medicine™

Products

DRAXIMAGE® MDP-25

Product Monograph

Click here to view Product Monograph

Indication

MDP-25 (Kit for the Preparation of Technetium Tc 99m Medronate) may be used as a bone imaging agent to delineate areas of altered osteogenesis.

The availability of technetium-based bone-seeking pharmaceuticals with improved soft-tissue clearance has led to sensitive, high-resolution images.

The skeleton is a complex system that performs several functions for the body including support, protection, movement, and blood formation via the blood marrow in some of the skeleton.

Radionuclide imaging of the skeleton is useful in the evaluation of osteoblastic abnormalities or altered osteogenesis involving bone and joints. This bone scintigraphy often provides an earlier, more sensitive diagnosis and often demonstrates more lesions than are found by common plain film radiographic procedures (metastatic disease, early osteomyelitis and avascular necrosis, stress fractures, occult fractures). Although the presence of a lesion on a bone scintigraphy can be non-specific in the absence of clinical information, its excellent sensitivity often provides important early recognition and direction for a complete differential diagnosis.

The addition of a clinical history, clinical correlation or complementary studies adds considerably specificity that allows a more definitive evaluation and diagnosis.

Product Overview

Product Name

Kit for the Preparation of Technetium Tc 99m Medronate Injection

Indications

MDP-25 (Kit for the Preparation of Technetium Tc 99m Medronate) may be used as a bone imaging agent to delineate areas of altered osteogenesis.

Contraindications

None known at present

Description

Each kit consists of reaction vials which contain the sterile, non-pyrogenic, non-radioactive ingredients necessary to produce Technetium Tc 99m Medronate Injection for diagnostic use by intravenous injection. Available in kits containing 30 reaction vials.

Note

  • MDP-25 reaction vials are intended to be used as multidose vials.
  • Care should be taken to ensure that each reconstituted dose of
    99mTc-MDP-25 contains between 1 and 10 mg of medronic acid. Refer to the Product Monograph for the detailed calculations.

Safety Data Sheet

Click here to view SDS

MDP / MDP-25 Canada Labelling Supplement Level II Submission Health Canada

Click here to view MDP-25

We use cookies to recognize your repeat visits and preferences, as well as to measure the effectiveness
of campaigns and analyze traffic. If you continue to use this site we will assume your acceptance.